Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis

被引：50

作者：

Reungwetwattana, Thanyanan ^{[1
]}

Adjei, Alex A. ^{[2
]}

机构：

[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Med Oncol,Dept Med, 270 Rama 6 Rd, Bangkok 10400, Thailand

[2] Mayo Clin, Dept Oncol, Rochester, MN USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 12期

关键词：

CELL LUNG-CANCER; NIVOLUMAB; INHIBITOR; DOCETAXEL; PATIENT;

D O I：

10.1016/j.jtho.2016.10.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently, cancer immunotherapy by immune checkpoint inhibitors has been considered one of the pillars for the treatment of cancer. Nivolumab is the first immune checkpoint inhibitor approved for lung cancer treatment in Japan. Although nivolumab has superior survival benefits and fewer adverse events than cytotoxic agents, it can generate dys-immune toxicities, known as immune-related adverse events. Although autoimmune manifestations are well-known immune-related adverse events, the development of infectious diseases is rare. Here, we report on a patient with advanced NSCLC in whom pulmonary tuberculosis developed rapidly during nivolumab treatment and discuss the potential mechanisms as well as what is known about infections during checkpoint inhibitor therapy. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：2048 / 2050

页数：3

共 20 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[3] Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities [J].

Cousin, Sophie ;

Italiano, Antoine .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4550-4555

[4] Tuberculosis in a patient on temozolomide: a case report [J].

de Paiva, Tadeu Ferreira, Jr. ;

de Barros e Silva, Milton Jose ;

Rinck, Jose Augusto, Jr. ;

Fanelli, Marcello Ferreti ;

Gimenes, Daniel Luiz .

JOURNAL OF NEURO-ONCOLOGY, 2009, 92 (01) :33-35

[5]

Fujita K, 2016, J THORAC ONCOL, V11, P2238, DOI 10.1016/j.jtho.2016.07.006

[6] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[7] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[8] Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis [J].

Jurado, Javier O. ;

Alvarez, Ivana B. ;

Pasquinelli, Virginia ;

Martinez, Gustavo J. ;

Quiroga, Maria F. ;

Abbate, Eduardo ;

Musella, Rosa M. ;

Chuluyan, H. Eduardo ;

Garcia, Veronica E. .

JOURNAL OF IMMUNOLOGY, 2008, 181 (01) :116-125

[9] How can immunology contribute to the control of tuberculosis? [J].

Kaufmann, SHE .

NATURE REVIEWS IMMUNOLOGY, 2001, 1 (01) :20-30

[10] Opportunistic infections in patients treated with immunotherapy for cancer [J].

Kyi, Chrisann ;

Hellmann, Matthew D. ;

Wolchok, Jedd D. ;

Chapman, Paul B. ;

Postow, Michael A. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2

← 1 2 →